MAPK14 and acute coronary syndrome: Losmapimod, which inhibits p38 mitogen-activated protein kinase, an enzyme which amplifies the inflammatory cascade through enhanced production of TNF-α, IL-6, and other cytokines, failed to improve outcome in the LATITUDE-TIMI 60 [Losmapimod to Inhibit p38 MAP (mitogen activated protein) Kinase as a Therapeutic Target and Modify Outcomes after an Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 60] study [11].